Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period.
This study evaluated enoxaparin alone versus initial enoxaparin followed by warfarin in secondary prevention of venous thromboembolic events in adults with active malignancy. Cancer patients (n = 122) with acute symptomatic venous thromboembolic events were randomly allocated to receive subcutaneous enoxaparin 1.0 mg/kg every 12 hours for 5 days, followed by 1.0 mg/kg daily (group 1a) or 1.5 mg/kg daily (group 1b) for 175 days, or subcutaneous enoxaparin 1.0 mg/kg every 12 hours for at least 5 days and until a stable international normalized ratio of 2 to 3 was achieved on oral warfarin begun on day 2 and continued to day 180 (group 2). There were no significant differences in major and minor bleeding rates between treatment groups. No bleeding events were intracranial or fatal. Enoxaparin treatment was feasible, generally well tolerated, and effective for a 180-day period in the secondary prevention of venous thromboembolic events in patients with active malignancy.
Deitcher
Steven R
SR
Section of Hematology and Coagulation Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA. sdeitcher@nuvelo.com
Kessler
Craig M
CM
Merli
Geno
G
Rigas
James R
JR
Lyons
Roger M
RM
Fareed
Jawed
J
D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D017984:Enoxaparin / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications* / Q000401:mortality; D012449:Safety; D016019:Survival Analysis; D013923:Thromboembolism / Q000517:prevention & control*; D014859:Warfarin / Q000627:therapeutic use*
D000925:Anticoagulants; D017984:Enoxaparin; D014859:Warfarin